Published in Cancer Res on February 01, 2005
Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol (2009) 5.55
Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo. Proc Natl Acad Sci U S A (2005) 1.04
Blocking translocation of cell surface molecules from the ER to the cell surface by intracellular antibodies targeted to the ER. J Cell Mol Med (2007) 0.90
Intracellular Acidosis Promotes Mitochondrial Apoptosis Pathway: Role of EMMPRIN Down-regulation via Specific Single-chain Fv Intrabody. J Cancer (2015) 0.83
A combinatorial approach for targeted delivery using small molecules and reversible masking to bypass nonspecific uptake in vivo. Gene Ther (2010) 0.83
The use of phage display to generate conformation-sensor recombinant antibodies. Nat Protoc (2012) 0.82
Antisense angiopoietin-1 inhibits tumorigenesis and angiogenesis of gastric cancer. World J Gastroenterol (2006) 0.82
Intrabody and Parkinson's disease. Biochim Biophys Acta (2008) 0.80
Specific in vivo knockdown of protein function by intrabodies. MAbs (2015) 0.80
Generation of anti-TLR2 intrabody mediating inhibition of macrophage surface TLR2 expression and TLR2-driven cell activation. BMC Biotechnol (2010) 0.78
From rabbit antibody repertoires to rabbit monoclonal antibodies. Exp Mol Med (2017) 0.78
Intrabody targeting vascular endothelial growth factor receptor-2 mediates downregulation of surface localization. Cancer Gene Ther (2016) 0.76
Targeting tumor vasculature through oncolytic virotherapy: recent advances. Oncolytic Virother (2015) 0.75
Monitoring the Growth of an Orthotopic Tumour Xenograft Model: Multi-Modal Imaging Assessment with Benchtop MRI (1T), High-Field MRI (9.4T), Ultrasound and Bioluminescence. PLoS One (2016) 0.75
Antibodies inside of a cell can change its outside: Can intrabodies provide a new therapeutic paradigm? Comput Struct Biotechnol J (2016) 0.75
Mining Naïve Rabbit Antibody Repertoires by Phage Display for Monoclonal Antibodies of Therapeutic Utility. J Mol Biol (2017) 0.75
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol (2013) 11.58
Interleukin-10 determines viral clearance or persistence in vivo. Nat Med (2006) 8.01
De novo computational design of retro-aldol enzymes. Science (2008) 7.62
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A (2003) 6.37
Engineering polydactyl zinc-finger transcription factors. Nat Biotechnol (2002) 4.40
Zinc Finger Tools: custom DNA-binding domains for transcription factors and nucleases. Nucleic Acids Res (2006) 3.95
Custom zinc-finger nucleases for use in human cells. Mol Ther (2005) 3.04
Myelomonocytic cell recruitment causes fatal CNS vascular injury during acute viral meningitis. Nature (2008) 2.87
Intrinsic functional dysregulation of CD4 T cells occurs rapidly following persistent viral infection. J Virol (2005) 2.75
Scanning the human genome with combinatorial transcription factor libraries. Nat Biotechnol (2003) 2.75
Development of zinc finger domains for recognition of the 5'-CNN-3' family DNA sequences and their use in the construction of artificial transcription factors. J Biol Chem (2005) 2.69
Directed evolution of an enhanced and highly efficient FokI cleavage domain for zinc finger nucleases. J Mol Biol (2010) 2.65
Bone marrow plasmacytoid dendritic cells can differentiate into myeloid dendritic cells upon virus infection. Nat Immunol (2004) 2.64
The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood (2010) 2.59
Viral persistence redirects CD4 T cell differentiation toward T follicular helper cells. J Exp Med (2011) 2.48
Designing transcription factor architectures for drug discovery. Mol Pharmacol (2004) 2.44
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood (2009) 2.39
Evaluation of a modular strategy for the construction of novel polydactyl zinc finger DNA-binding proteins. Biochemistry (2003) 2.33
IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection. J Exp Med (2008) 2.20
Viral targeting of hematopoietic progenitors and inhibition of DC maturation as a dual strategy for immune subversion. J Clin Invest (2004) 2.11
A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood (2011) 2.09
Targeted gene knockout by direct delivery of zinc-finger nuclease proteins. Nat Methods (2012) 2.07
Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science (2004) 2.00
Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res (2008) 1.95
Synthesis of programmable integrases. Proc Natl Acad Sci U S A (2009) 1.94
The Nogo-66 receptor homolog NgR2 is a sialic acid-dependent receptor selective for myelin-associated glycoprotein. J Neurosci (2005) 1.93
Enamine-based organocatalysis with proline and diamines: the development of direct catalytic asymmetric Aldol, Mannich, Michael, and Diels-alder reactions. Acc Chem Res (2004) 1.92
Structure of Aart, a designed six-finger zinc finger peptide, bound to DNA. J Mol Biol (2006) 1.91
Modular system for the construction of zinc-finger libraries and proteins. Nat Protoc (2010) 1.87
Rapid, stable, chemoselective labeling of thiols with Julia-Kocieński-like reagents: a serum-stable alternative to maleimide-based protein conjugation. Angew Chem Int Ed Engl (2013) 1.85
Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res (2013) 1.85
Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst. Proc Natl Acad Sci U S A (2003) 1.78
Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest. Proc Natl Acad Sci U S A (2009) 1.72
Biochemical characterization and structural analysis of a highly proficient cocaine esterase. Biochemistry (2002) 1.60
Reprogramming of antiviral T cells prevents inactivation and restores T cell activity during persistent viral infection. J Clin Invest (2006) 1.59
A viral epitope that mimics a self antigen can accelerate but not initiate autoimmune diabetes. J Clin Invest (2004) 1.51
Implications of the HIV-1 Rev dimer structure at 3.2 A resolution for multimeric binding to the Rev response element. Proc Natl Acad Sci U S A (2010) 1.51
PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. J Exp Med (2013) 1.48
Microglia development and function. Annu Rev Immunol (2014) 1.41
Chimeric TALE recombinases with programmable DNA sequence specificity. Nucleic Acids Res (2012) 1.38
Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector. Int J Cancer (2006) 1.37
Heritable endogenous gene regulation in plants with designed polydactyl zinc finger transcription factors. Proc Natl Acad Sci U S A (2002) 1.34
In vivo site-specific DNA methylation with a designed sequence-enabled DNA methylase. J Am Chem Soc (2007) 1.33
Structure-guided reprogramming of serine recombinase DNA sequence specificity. Proc Natl Acad Sci U S A (2010) 1.31
Evolution of aldolase antibodies in vitro: correlation of catalytic activity and reaction-based selection. J Mol Biol (2004) 1.30
Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood (2010) 1.30
Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display. J Mol Biol (2003) 1.30
Exploring strategies for the design of artificial transcription factors: targeting sites proximal to known regulatory regions for the induction of gamma-globin expression and the treatment of sickle cell disease. J Biol Chem (2004) 1.30
Chemical adaptor immunotherapy: design, synthesis, and evaluation of novel integrin-targeting devices. J Med Chem (2004) 1.29
Evolution of programmable zinc finger-recombinases with activity in human cells. J Mol Biol (2007) 1.28
Breaking the one antibody-one target axiom. Proc Natl Acad Sci U S A (2006) 1.26
Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc Natl Acad Sci U S A (2009) 1.26
Direct asymmetric alpha-fluorination of aldehydes. Angew Chem Int Ed Engl (2005) 1.25
Instant immunity through chemically programmable vaccination and covalent self-assembly. Proc Natl Acad Sci U S A (2009) 1.25
Attenuation of HIV-1 replication in primary human cells with a designed zinc finger transcription factor. J Biol Chem (2004) 1.24
Molecularly defined antibody conjugation through a selenocysteine interface. Biochemistry (2009) 1.23
Chemically programmed antibodies: endothelin receptor targeting CovX-Bodies. Bioorg Med Chem Lett (2006) 1.22
Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PLoS One (2011) 1.21
Lymphocytic choriomeningitis infection of the central nervous system. Front Biosci (2008) 1.21
An engineered selenocysteine defines a unique class of antibody derivatives. Proc Natl Acad Sci U S A (2008) 1.21
Fusion proteins consisting of human immunodeficiency virus type 1 integrase and the designed polydactyl zinc finger protein E2C direct integration of viral DNA into specific sites. J Virol (2004) 1.20
Directed evolution of recombinase specificity by split gene reassembly. Nucleic Acids Res (2010) 1.19
Adoptive immunotherapy induces CNS dendritic cell recruitment and antigen presentation during clearance of a persistent viral infection. J Exp Med (2006) 1.16
Core-structure-motivated design of a phosphine-catalyzed [3+2] cycloaddition reaction: enantioselective syntheses of spirocyclopenteneoxindoles. J Am Chem Soc (2011) 1.15
Towards organo-click chemistry: development of organocatalytic multicomponent reactions through combinations of aldol, Wittig, Knoevenagel, Michael, Diels-Alder and Huisgen cycloaddition reactions. Chemistry (2004) 1.14
Targeted plasmid integration into the human genome by an engineered zinc-finger recombinase. Nucleic Acids Res (2011) 1.13
Organocatalytic asymmetric domino knoevenagel/diels-alder reactions: a bioorganic approach to the diastereospecific and enantioselective construction of highly substituted spiro[5,5]undecane-1,5,9-triones. Angew Chem Int Ed Engl (2003) 1.12
Development of small designer aldolase enzymes: catalytic activity, folding, and substrate specificity. Biochemistry (2005) 1.12
Mechanisms of CNS myelin inhibition: evidence for distinct and neuronal cell type specific receptor systems. Restor Neurol Neurosci (2008) 1.12
Integrin alpha(v)beta3 targeted therapy for Kaposi's sarcoma with an in vitro evolved antibody. FASEB J (2002) 1.11
A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy. J Mol Biol (2003) 1.11
An efficient chemical approach to bispecific antibodies and antibodies of high valency. Bioorg Med Chem Lett (2009) 1.11
The origin of enantioselectivity in aldolase antibodies: crystal structure, site-directed mutagenesis, and computational analysis. J Mol Biol (2004) 1.10
Preparation of integrin alpha(v)beta3-targeting Ab 38C2 constructs. Nat Protoc (2007) 1.10
A modular assembly strategy for improving the substrate specificity of small catalytic peptides. J Am Chem Soc (2002) 1.09
Tyrosine bioconjugation through aqueous ene-type reactions: a click-like reaction for tyrosine. J Am Chem Soc (2010) 1.08
Molecular basis of the interactions of the Nogo-66 receptor and its homolog NgR2 with myelin-associated glycoprotein: development of NgROMNI-Fc, a novel antagonist of CNS myelin inhibition. J Neurosci (2009) 1.08
Directed evolution of the TALE N-terminal domain for recognition of all 5' bases. Nucleic Acids Res (2013) 1.08
Genetic reprogramming of tumor cells by zinc finger transcription factors. Proc Natl Acad Sci U S A (2005) 1.07
Visualizing the viral burden: phenotypic and functional alterations of T cells and APCs during persistent infection. J Immunol (2004) 1.07
Inhibition of human immunodeficiency virus type 1 replication with artificial transcription factors targeting the highly conserved primer-binding site. J Virol (2006) 1.07
A novel high-affinity human monoclonal antibody to mesothelin. Int J Cancer (2011) 1.06
{gamma}-Globin gene expression in chemical inducer of dimerization (CID)-dependent multipotential cells established from human {beta}-globin locus yeast artificial chromosome ({beta}-YAC) transgenic mice. J Biol Chem (2005) 1.06
Synthetic zinc finger proteins: the advent of targeted gene regulation and genome modification technologies. Acc Chem Res (2014) 1.06
A comprehensive approach to zinc-finger recombinase customization enables genomic targeting in human cells. Nucleic Acids Res (2013) 1.04
Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo. Proc Natl Acad Sci U S A (2005) 1.04
Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activation. Proc Natl Acad Sci U S A (2007) 1.04
Migration of cytotoxic lymphocytes in cell cycle permits local MHC I-dependent control of division at sites of viral infection. J Exp Med (2011) 1.03
Beta-lactam-based approach for the chemical programming of aldolase antibody 38C2. Bioorg Med Chem Lett (2009) 1.03
A highly enantioselective route to either enantiomer of both alpha- and beta-amino acid derivatives. J Am Chem Soc (2002) 1.03
A highly enantioselective amino acid-catalyzed route to functionalized alpha-amino acids. J Am Chem Soc (2002) 1.03